There are 2137 resources available
LBA15 - Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC)
Presenter: David Miles
Session: Proffered Paper - Breast cancer, metastatic 1
Resources:
Abstract
Slides
Webcast
LBA16 - IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer
Presenter: Leisha Emens
Session: Proffered Paper - Breast cancer, metastatic 1
Resources:
Abstract
Slides
Webcast
LBA17 - ASCENT: A randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC)
Presenter: Aditya Bardia
Session: Proffered Paper - Breast cancer, metastatic 1
Resources:
Abstract
Slides
Webcast
LBA18 - Overall survival (os) results from SOLAR-1, a phase III study of alpelisib (ALP) + fulvestrant (FUL) for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC)
Presenter: Fabrice André
Session: Proffered Paper - Breast cancer, metastatic 1
Resources:
Abstract
Slides
Webcast
273O - nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, HER2- metastatic breast cancer
Presenter: Erika Hamilton
Session: Proffered Paper - Breast cancer, metastatic 1
Resources:
Abstract
Slides
Webcast
LBA43 - Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial
Presenter: Paul Nathan
Session: Proffered Paper - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
LBA44 - Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004
Presenter: Ana Maria Arance Fernandez
Session: Proffered Paper - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
LBA45 - First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo Immuno and Targeted therapy study)
Presenter: Paolo Ascierto
Session: Proffered Paper - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
LBA46 - Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Final results regarding distant metastasis-free survival from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial
Presenter: Alexander Eggermont
Session: Proffered Paper - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
1076O - Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238
Presenter: Jeffrey Weber
Session: Proffered Paper - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast